Operational and Pharmacist Considerations for Bispecific Antibodies in EGFR-Mutated NSCLC

This discussion focuses on the operational considerations of using bispecific antibodies in EGFR-mutated non–small cell lung cancer (NSCLC), including dosing schedules, Risk Evaluation and Mitigation Strategies (REMS), and transitions of care. Panelists will explore how these factors impact both clinical workflow and patient experience, highlighting practical challenges and opportunities for streamlining treatment delivery. The role of pharmacists will be emphasized, including oversight of REMS requirements, patient education, adherence monitoring, and coordination across care settings. Additionally, the session will examine the potential benefits and limitations of every-four-week dosing schedules, considering how extended intervals might affect convenience, safety monitoring, and patient-provider communication. By addressing these operational and clinical nuances, this discussion provides guidance for optimizing the safe and effective integration of bispecific antibodies into NSCLC treatment regimens.